Skip to main content
Top
Published in: BMC Pediatrics 1/2019

Open Access 01-12-2019 | Joint Pain | Case report

A case report of mevalonate kinase deficiency in a 14-month-old female with fevers and lower extremity weakness

Authors: Tiziana Coppola, Bradford Becken, Heather Van Mater, Marie Theresa McDonald, Gabriela Maradiaga Panayotti

Published in: BMC Pediatrics | Issue 1/2019

Login to get access

Abstract

Background

This case follows a 14-month-old female, who despite multiple presentations to several physicians, continued to have recurrent febrile episodes with gross motor delay. Her case revealed an often missed diagnosis of Mevalonate Kinase Deficiency, that now has an FDA approved treatment that both reduces recurrence and produces remission.

Case presentation

A 14-month-old female with a history of gross motor delay, frequent Upper Respiratory Tract infections, and otitis media presented to an urgent care for inconsolability and refusal to bear weight on her right leg. She had recently been treated with amoxicillin for acute otitis media and had developed a diffuse maculopapular rash, without any associated respiratory or gastrointestinal distress that persisted beyond cessation of the antibiotics. The patient presented multiple times to an urgent care over the subsequent week for fussiness, fever, anorexia, lymphadenopathy, with labs concerning for worsening anemia and elevated inflammatory markers. Subsequently, the patient was admitted to the hospital for suspected osteomyelitis versus oncologic process. X-Ray imaging of the patient’s lower extremities showed osseous abnormalities inconsistent with infection. A metabolic work-up showed elevated urine mevalonic acid, and follow-up genetic testing was positive for mutations in both copies of her mevalonate kinase gene. This led to the diagnosis of MKD.

Conclusions

Often, episodic presentations require multiple perspectives to reveal the underlying cause. This case illustrates how apparent simple febrile episodes has the potential for more complexity upon further evaluation.
Literature
1.
go back to reference van der Hilst JC, Frenkel J. Hyperimmunoglobulin D syndrome in childhood. Curr Rheumatol Rep. 2010;12(2):101–7.CrossRef van der Hilst JC, Frenkel J. Hyperimmunoglobulin D syndrome in childhood. Curr Rheumatol Rep. 2010;12(2):101–7.CrossRef
2.
go back to reference Zhang S. Natural history of mevalonate kinase deficiency: a literature review. Pediatr Rheumatol Online J. 2016;14(1):30.CrossRef Zhang S. Natural history of mevalonate kinase deficiency: a literature review. Pediatr Rheumatol Online J. 2016;14(1):30.CrossRef
3.
go back to reference Favier LA, Schulert GS. Mevalonate kinase deficiency: current perspectives. Appl Clin Genet. 2016;9:101–10.CrossRef Favier LA, Schulert GS. Mevalonate kinase deficiency: current perspectives. Appl Clin Genet. 2016;9:101–10.CrossRef
4.
go back to reference Haas D, Hoffmann GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis. 2006;1:13 5.CrossRef Haas D, Hoffmann GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis. 2006;1:13 5.CrossRef
5.
go back to reference Aygun D, Sahin S, Cokugras H, et al. Hyperimmunoglobulinaemia D syndrome: a rare cause of prolonged fever and treatment with anti-interleukin 1 agent. BMJ Case Rep. 2016:17, 2016. Aygun D, Sahin S, Cokugras H, et al. Hyperimmunoglobulinaemia D syndrome: a rare cause of prolonged fever and treatment with anti-interleukin 1 agent. BMJ Case Rep. 2016:17, 2016.
6.
go back to reference Van der Burgh R, ter Haar NM, Boes ML, et al. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin Immunol. 2013;147(3):197–206 6.CrossRef Van der Burgh R, ter Haar NM, Boes ML, et al. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin Immunol. 2013;147(3):197–206 6.CrossRef
7.
go back to reference Korppi M, Van Gijn ME, Antila K. Hyperimmunoglobulinemia D and periodic fever syndrome in children. Review on therapy with biological drugs and case report. Acta Paediatr. 2011;100(1):21–5 8.CrossRef Korppi M, Van Gijn ME, Antila K. Hyperimmunoglobulinemia D and periodic fever syndrome in children. Review on therapy with biological drugs and case report. Acta Paediatr. 2011;100(1):21–5 8.CrossRef
8.
go back to reference Kostjukovits S, Kalliokoski L, Antila K, et al. Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience. Eur J Pediatr. 2015;174(6):707–14.CrossRef Kostjukovits S, Kalliokoski L, Antila K, et al. Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience. Eur J Pediatr. 2015;174(6):707–14.CrossRef
9.
go back to reference Peciuliene S, Burnyte B, Gudaitiene R, et al. Perinatal manifestation of mevalonate kinase deficiency and efficacy of anakinra. Pediatr Rheumatol Online J. 2016;14(1):19.CrossRef Peciuliene S, Burnyte B, Gudaitiene R, et al. Perinatal manifestation of mevalonate kinase deficiency and efficacy of anakinra. Pediatr Rheumatol Online J. 2016;14(1):19.CrossRef
10.
go back to reference Arostegui JI, Anton J, Calvo I, et al. Open-label, phase II study to assess the efficacy and safety of canakinumab treatment in active hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheumatol. 2017;69(8):1679–88.CrossRef Arostegui JI, Anton J, Calvo I, et al. Open-label, phase II study to assess the efficacy and safety of canakinumab treatment in active hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheumatol. 2017;69(8):1679–88.CrossRef
11.
go back to reference Bodar EJ, Kuijk LM, Drenth JP, et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis. 2011;70(12):2155–8.CrossRef Bodar EJ, Kuijk LM, Drenth JP, et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis. 2011;70(12):2155–8.CrossRef
12.
go back to reference Galeotti C, Meinzer U, Quartier P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford). 2012;51(10):1855–9.CrossRef Galeotti C, Meinzer U, Quartier P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford). 2012;51(10):1855–9.CrossRef
13.
go back to reference Tsitsami E, Papadopoulou C, Speletas M. A case of hyperimmunoglobulinemia D syndrome successfully treated with canakinumab. Case Rep Rheumatol. 2013;2013:795027 1–4.PubMedPubMedCentral Tsitsami E, Papadopoulou C, Speletas M. A case of hyperimmunoglobulinemia D syndrome successfully treated with canakinumab. Case Rep Rheumatol. 2013;2013:795027 1–4.PubMedPubMedCentral
14.
go back to reference De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378(20):1908–19.CrossRef De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378(20):1908–19.CrossRef
15.
go back to reference Di Gangi M, Amato G, Converso G, et al. Long-term efficacy of adalimumab in hyper- immunoglobulin D and periodic fever syndrome. Isr Med Assoc J. 2014;16:605–7.PubMed Di Gangi M, Amato G, Converso G, et al. Long-term efficacy of adalimumab in hyper- immunoglobulin D and periodic fever syndrome. Isr Med Assoc J. 2014;16:605–7.PubMed
16.
go back to reference Cantarini L, Vitale A, Magnotti F, et al. Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J Rare Dis. 2013;8(1):196.CrossRef Cantarini L, Vitale A, Magnotti F, et al. Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J Rare Dis. 2013;8(1):196.CrossRef
17.
go back to reference Mulders-Manders CM, Simon A. Hyper-IgD syndrome/mevalonate kinase deficiency: what is new? Semin Immunopathol. 2015;37(4):371–6.CrossRef Mulders-Manders CM, Simon A. Hyper-IgD syndrome/mevalonate kinase deficiency: what is new? Semin Immunopathol. 2015;37(4):371–6.CrossRef
18.
go back to reference Simon A, Drewe E, van der Meer JW, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther. 2004;75(5):476–83.CrossRef Simon A, Drewe E, van der Meer JW, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther. 2004;75(5):476–83.CrossRef
19.
go back to reference Chaudhury S, Hormaza L, Mohammad S, et al. Liver transplantation followed by allogeneic hematopoietic stem cell transplantation for atypical mevalonic aciduria. Am J Transplant. 2012;12(6):1627–31.CrossRef Chaudhury S, Hormaza L, Mohammad S, et al. Liver transplantation followed by allogeneic hematopoietic stem cell transplantation for atypical mevalonic aciduria. Am J Transplant. 2012;12(6):1627–31.CrossRef
20.
go back to reference Giardino S, Lanino E, Morreale G, et al. Long-term outcome of a successful cord blood stem cell transplant in mevalonate kinase deficiency. Pediatrics. 2015;135(1):e211–5.CrossRef Giardino S, Lanino E, Morreale G, et al. Long-term outcome of a successful cord blood stem cell transplant in mevalonate kinase deficiency. Pediatrics. 2015;135(1):e211–5.CrossRef
21.
go back to reference Neven B, Valayannopoulos V, Quartier P, et al. Allogenic bone marrow transplantation in mevalonic aciduria. N Engl J Med. 2007;356(26):2700–3.CrossRef Neven B, Valayannopoulos V, Quartier P, et al. Allogenic bone marrow transplantation in mevalonic aciduria. N Engl J Med. 2007;356(26):2700–3.CrossRef
Metadata
Title
A case report of mevalonate kinase deficiency in a 14-month-old female with fevers and lower extremity weakness
Authors
Tiziana Coppola
Bradford Becken
Heather Van Mater
Marie Theresa McDonald
Gabriela Maradiaga Panayotti
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2019
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-019-1617-1

Other articles of this Issue 1/2019

BMC Pediatrics 1/2019 Go to the issue